Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista CollTech to gain European bakery expert as shareholder

Holista CollTech to gain European bakery expert as shareholder

Holista Colltech (ASX:HCT) will issue shares up to a 10% stake to the major shareholder of Swiss Panadoro Group and Matzingen-based Veripan AG, Europe’s largest independent supplier of specialty baking ingredients.

Holista, which recently announced a scientific breakthrough to make white bread healthier with its combination of a blend of okra, lentils, barley and fenugreek with Veripan’s sourdough formula to form PANATURA® GI, will sell shares and free attaching options to Meiert Grootes in tranches.

Grootes will acquire the shares at $0.115 amounting to A$454,734, via a direct placement, equal to a 2.5% holding.

Free attached options will be issued for 11,862,616 new shares, which will enlarge his stake in Holista by a further 7.5% exercisable at various strike prices.

Holista's patented formula scored a Glycemic Index (“GI”) reading of 53, the lowest-ever achieved by any clean-label white bread in a clinical trial.

It will begin marketing PANATURA® GI to the US$170 billion white bread market, a rollout in which Grootes will play a significant role given his 27 years’ experience in the bread industry and contacts in the milling and bakery industry.

Clearly, interesting times are ahead in the roll-out of the product.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.





Register here to be notified of future HCT Company articles
View full HCT profile View Profile

Holista Colltech Ltd Timeline

Newswire
September 19 2017

Related Articles

1504120610_biotechLatest.jpg
October 24 2017
The company is poised for a milestone-rich period over the next year or so
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use